A new scientific study published in The New England Journal of Medicine has revealed promising results in the treatment of CPS1 enzyme deficiency, one of the most serious and rare urea cycle disorders.

The congenital condition, with an estimated incidence of approximately 1 in every 800,000 to 1,300,000 live births, causes the accumulation of ammonia, which is toxic to the brain (hyperammonaemia), causing premature death in half of the patients if they are not treated (newborns without the enzyme die within 72 hours).

The correction of the genetic defect in the affected baby (KJ) was performed using a personalized gene therapy based on the second generation of the CRISPR gene editing tool, administered via lipid nanoparticles.

Available treatments are limited and often result in unfavorable neurological outcomes.

This therapeutic milestone, which represents a decisive opportunity to treat CPS1 deficiency, achieved positive results just seven weeks after the doses were administered.

A scientific study published in The New England Journal of Medicine shows promising results in the treatment of a rare congenital disorder consisting of a deficiency of the CPS1 enzyme.

This disease is one of the most serious and rare urea cycle disorders: its estimated incidence is approximately 1 in 800,000 to 1 in 1,300,000 live births.

CPS1 is an enzyme that catalyses the urea cycle: the conversion of ammonia and bicarbonate into carbamoyl phosphate. Without functional CPS1, ammonia accumulates in the bloodstream and causes hyperammonaemia, which is toxic to the brain and can lead to coma or death if left untreated.

The condition known as carbamoyl phosphate synthetase 1 (CPS1) deficiency causes premature death in half of those affected. Children born without CPSI1 die within 72 hours if left untreated.

Currently, available treatments are limited and may include dialysis, ammonia scavengers, protein restriction, and, subsequently, liver transplantation, although neurological outcomes are often unfavorable.

Correcting the defect that causes this deficiency using gene-editing techniques represents a compelling therapeutic opportunity for babies with CPS1 deficiency and other urea cycle disorders.

The doctors who treated KJ had been working since 2023 on personalised gene therapy for patients with metabolic diseases and decided to focus on problems related to the urea cycle.

After years of research, when KJ’s case came to them, they designed a personalized treatment to correct the defective enzyme in about six months. In February, at six months old, he received the first dose, and then two more in March and April.

The treatment used on KJ is the second generation of the CRISPR gene-editing tool and was developed in record time. After administering the doses, the results were visible within seven weeks.

In KJ’s case, the genetic alteration, inherited from his father, was treated using a lipid nanoparticle therapy, similar to that used in messenger RNA vaccines.

Currently, the treatment doses have been reduced to half of those initially used, with no serious adverse effects detected.

The monitoring of the patient’s progress has been limited, given that the treatment began a few months ago, so it is not possible to predict the long-term future evolution, whether there will be relapses, or if the treatment will continue to work.

Advances and future of gene therapy

As ​​we have previously published in our Observatory, this is not the first advance in the clinical application of treatments that use gene editing techniques.

Effective treatments have been developed for mitochondrial diseases, leukocyte adhesion deficiency type I (LAD-I), Fanconi anemia, congenital deafness, spinal muscular atrophy, hemophilia A, and Gaucher disease in the fetus.

This demonstrates that the refinement of gene editing using the CRISPR technique allows for its successful application in clinical practice, making it possible to cure diseases for which such treatment was previously unavailable.

Both the refinement and sophistication of these techniques allow us to address new pathologies, reduce errors and increase their effectiveness, with advances such as “prime editing” or “database editors”.

However, the scope of gene editing is limited, extremely expensive, and has safety and efficacy problems, so its extension to all patients who need it does not seem likely to happen anytime soon.

Making these procedures cheaper to increase their availability and reducing the time required for their implementation appear as urgent challenges in these therapeutic measures related to gene editing.

Julio Tudela and Ester Bosch

Bioethics Observatory – Institute of Life Sciences

Catholic University of Valencia

 

Share This Story, Choose Your Platform!